img

Global Cancer Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cancer Vaccines Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Cancer is the second leading cause of morbidity and mortality worldwide. Major cause of cancer is gene mutation and rarely due to inherited genes.
The global Cancer Vaccines market size was US$ 4755.6 million in 2024 and is forecast to a readjusted size of US$ 12220 million by 2034 with a CAGR of 14.3% during the forecast period 2024-2034.
Factors such as increasing number of people with cancer, rising public awareness of vaccines, presence of promising late-stage pipeline candidates, and vendors' patient-assistance programs also augment growth in the cancer vaccines market. Dendritic cells are cells taken from a patient's immune system and treated with chemicals before being injected back into the patient. These cells produce an enhanced immune response against the malignant cells in the body and stimulate the other cells in the immune system to fight the cancerous cells.
In terms of sales (consumption) side, this report focuses on the sales of Cancer Vaccines by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Cancer Vaccines market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Cancer Vaccines market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Glaxosmithkline
Astellas Pharma
Merck
CSL Limited
Sanpower Group
Sanofi Pasteur
Pfizer
Serum Institute of India
By Type
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
By Application
Cervical Cancer
Prostate Cancer
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Cancer Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Cancer Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Cancer Vaccines Definition
1.2 Market by Type
1.2.1 Global Cancer Vaccines Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Preventive Cancer Vaccines
1.2.3 Therapeutic Cancer Vaccines
1.3 Market Segment by Application
1.3.1 Global Cancer Vaccines Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Cervical Cancer
1.3.3 Prostate Cancer
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Cancer Vaccines Sales
2.1 Global Cancer Vaccines Revenue Estimates and Forecasts 2018-2034
2.2 Global Cancer Vaccines Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Cancer Vaccines Revenue by Region
2.3.1 Global Cancer Vaccines Revenue by Region (2018-2023)
2.3.2 Global Cancer Vaccines Revenue by Region (2024-2034)
2.4 Global Cancer Vaccines Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Cancer Vaccines Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Cancer Vaccines Sales Quantity by Region
2.6.1 Global Cancer Vaccines Sales Quantity by Region (2018-2023)
2.6.2 Global Cancer Vaccines Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Cancer Vaccines Sales Quantity by Manufacturers
3.1.1 Global Cancer Vaccines Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Cancer Vaccines Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Cancer Vaccines Sales in 2024
3.2 Global Cancer Vaccines Revenue by Manufacturers
3.2.1 Global Cancer Vaccines Revenue by Manufacturers (2018-2023)
3.2.2 Global Cancer Vaccines Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Cancer Vaccines Revenue in 2024
3.3 Global Cancer Vaccines Sales Price by Manufacturers
3.4 Global Key Players of Cancer Vaccines, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Cancer Vaccines, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Cancer Vaccines, Product Offered and Application
3.8 Global Key Manufacturers of Cancer Vaccines, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Cancer Vaccines Sales Quantity by Type
4.1.1 Global Cancer Vaccines Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Cancer Vaccines Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Cancer Vaccines Sales Quantity Market Share by Type (2018-2034)
4.2 Global Cancer Vaccines Revenue by Type
4.2.1 Global Cancer Vaccines Historical Revenue by Type (2018-2023)
4.2.2 Global Cancer Vaccines Forecasted Revenue by Type (2024-2034)
4.2.3 Global Cancer Vaccines Revenue Market Share by Type (2018-2034)
4.3 Global Cancer Vaccines Price by Type
4.3.1 Global Cancer Vaccines Price by Type (2018-2023)
4.3.2 Global Cancer Vaccines Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Cancer Vaccines Sales Quantity by Application
5.1.1 Global Cancer Vaccines Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Cancer Vaccines Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Cancer Vaccines Sales Quantity Market Share by Application (2018-2034)
5.2 Global Cancer Vaccines Revenue by Application
5.2.1 Global Cancer Vaccines Historical Revenue by Application (2018-2023)
5.2.2 Global Cancer Vaccines Forecasted Revenue by Application (2024-2034)
5.2.3 Global Cancer Vaccines Revenue Market Share by Application (2018-2034)
5.3 Global Cancer Vaccines Price by Application
5.3.1 Global Cancer Vaccines Price by Application (2018-2023)
5.3.2 Global Cancer Vaccines Price Forecast by Application (2024-2034)
6 North America
6.1 North America Cancer Vaccines Sales by Company
6.1.1 North America Cancer Vaccines Revenue by Company (2018-2023)
6.1.2 North America Cancer Vaccines Sales Quantity by Company (2018-2023)
6.2 North America Cancer Vaccines Market Size by Type
6.2.1 North America Cancer Vaccines Sales Quantity by Type (2018-2034)
6.2.2 North America Cancer Vaccines Revenue by Type (2018-2034)
6.3 North America Cancer Vaccines Market Size by Application
6.3.1 North America Cancer Vaccines Sales Quantity by Application (2018-2034)
6.3.2 North America Cancer Vaccines Revenue by Application (2018-2034)
6.4 North America Cancer Vaccines Market Size by Country
6.4.1 North America Cancer Vaccines Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Cancer Vaccines Revenue by Country (2018-2034)
6.4.3 North America Cancer Vaccines Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Cancer Vaccines Sales by Company
7.1.1 Europe Cancer Vaccines Sales Quantity by Company (2018-2023)
7.1.2 Europe Cancer Vaccines Revenue by Company (2018-2023)
7.2 Europe Cancer Vaccines Market Size by Type
7.2.1 Europe Cancer Vaccines Sales Quantity by Type (2018-2034)
7.2.2 Europe Cancer Vaccines Revenue by Type (2018-2034)
7.3 Europe Cancer Vaccines Market Size by Application
7.3.1 Europe Cancer Vaccines Sales Quantity by Application (2018-2034)
7.3.2 Europe Cancer Vaccines Revenue by Application (2018-2034)
7.4 Europe Cancer Vaccines Market Size by Country
7.4.1 Europe Cancer Vaccines Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Cancer Vaccines Revenue by Country (2018-2034)
7.4.3 Europe Cancer Vaccines Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Cancer Vaccines Sales by Company
8.1.1 China Cancer Vaccines Sales Quantity by Company (2018-2023)
8.1.2 China Cancer Vaccines Revenue by Company (2018-2023)
8.2 China Cancer Vaccines Market Size by Type
8.2.1 China Cancer Vaccines Sales Quantity by Type (2018-2034)
8.2.2 China Cancer Vaccines Revenue by Type (2018-2034)
8.3 China Cancer Vaccines Market Size by Application
8.3.1 China Cancer Vaccines Sales Quantity by Application (2018-2034)
8.3.2 China Cancer Vaccines Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Cancer Vaccines Sales by Company
9.1.1 APAC Cancer Vaccines Sales Quantity by Company (2018-2023)
9.1.2 APAC Cancer Vaccines Revenue by Company (2018-2023)
9.2 APAC Cancer Vaccines Market Size by Type
9.2.1 APAC Cancer Vaccines Sales Quantity by Type (2018-2034)
9.2.2 APAC Cancer Vaccines Revenue by Type (2018-2034)
9.3 APAC Cancer Vaccines Market Size by Application
9.3.1 APAC Cancer Vaccines Sales Quantity by Application (2018-2034)
9.3.2 APAC Cancer Vaccines Revenue by Application (2018-2034)
9.4 APAC Cancer Vaccines Market Size by Region
9.4.1 APAC Cancer Vaccines Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Cancer Vaccines Revenue by Region (2018-2034)
9.4.3 APAC Cancer Vaccines Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Cancer Vaccines Sales by Company
10.1.1 Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Cancer Vaccines Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Cancer Vaccines Market Size by Type
10.2.1 Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Cancer Vaccines Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Cancer Vaccines Market Size by Application
10.3.1 Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Cancer Vaccines Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Cancer Vaccines Market Size by Country
10.4.1 Middle East, Africa and Latin America Cancer Vaccines Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Cancer Vaccines Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Glaxosmithkline
11.1.1 Glaxosmithkline Company Information
11.1.2 Glaxosmithkline Overview
11.1.3 Glaxosmithkline Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Glaxosmithkline Cancer Vaccines Products and Services
11.1.5 Glaxosmithkline Cancer Vaccines SWOT Analysis
11.1.6 Glaxosmithkline Recent Developments
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Information
11.2.2 Astellas Pharma Overview
11.2.3 Astellas Pharma Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Astellas Pharma Cancer Vaccines Products and Services
11.2.5 Astellas Pharma Cancer Vaccines SWOT Analysis
11.2.6 Astellas Pharma Recent Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck Overview
11.3.3 Merck Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Merck Cancer Vaccines Products and Services
11.3.5 Merck Cancer Vaccines SWOT Analysis
11.3.6 Merck Recent Developments
11.4 CSL Limited
11.4.1 CSL Limited Company Information
11.4.2 CSL Limited Overview
11.4.3 CSL Limited Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 CSL Limited Cancer Vaccines Products and Services
11.4.5 CSL Limited Cancer Vaccines SWOT Analysis
11.4.6 CSL Limited Recent Developments
11.5 Sanpower Group
11.5.1 Sanpower Group Company Information
11.5.2 Sanpower Group Overview
11.5.3 Sanpower Group Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Sanpower Group Cancer Vaccines Products and Services
11.5.5 Sanpower Group Cancer Vaccines SWOT Analysis
11.5.6 Sanpower Group Recent Developments
11.6 Sanofi Pasteur
11.6.1 Sanofi Pasteur Company Information
11.6.2 Sanofi Pasteur Overview
11.6.3 Sanofi Pasteur Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Sanofi Pasteur Cancer Vaccines Products and Services
11.6.5 Sanofi Pasteur Cancer Vaccines SWOT Analysis
11.6.6 Sanofi Pasteur Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Overview
11.7.3 Pfizer Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Pfizer Cancer Vaccines Products and Services
11.7.5 Pfizer Cancer Vaccines SWOT Analysis
11.7.6 Pfizer Recent Developments
11.8 Serum Institute of India
11.8.1 Serum Institute of India Company Information
11.8.2 Serum Institute of India Overview
11.8.3 Serum Institute of India Cancer Vaccines Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Serum Institute of India Cancer Vaccines Products and Services
11.8.5 Serum Institute of India Cancer Vaccines SWOT Analysis
11.8.6 Serum Institute of India Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Cancer Vaccines Value Chain Analysis
12.2 Cancer Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cancer Vaccines Production Mode & Process
12.4 Cancer Vaccines Sales and Marketing
12.4.1 Cancer Vaccines Sales Channels
12.4.2 Cancer Vaccines Distributors
12.5 Cancer Vaccines Customers
13 Market Dynamics
13.1 Cancer Vaccines Industry Trends
13.2 Cancer Vaccines Market Drivers
13.3 Cancer Vaccines Market Challenges
13.4 Cancer Vaccines Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Cancer Vaccines Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Preventive Cancer Vaccines
Table 3. Major Manufacturers of Therapeutic Cancer Vaccines
Table 4. Global Cancer Vaccines Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Cancer Vaccines Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Cancer Vaccines Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Cancer Vaccines Revenue Market Share by Region (2018-2023)
Table 8. Global Cancer Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Cancer Vaccines Revenue Market Share by Region (2024-2034)
Table 10. Global Cancer Vaccines Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 11. Global Cancer Vaccines Sales by Region (2018-2023) & (K Units)
Table 12. Global Cancer Vaccines Sales Market Share by Region (2018-2023)
Table 13. Global Cancer Vaccines Sales by Region (2024-2034) & (K Units)
Table 14. Global Cancer Vaccines Sales Market Share by Region (2024-2034)
Table 15. Global Cancer Vaccines Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 16. Global Cancer Vaccines Sales Quantity Share by Manufacturers (2018-2023)
Table 17. Global Cancer Vaccines Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Cancer Vaccines Revenue Share by Manufacturers (2018-2023)
Table 19. Global Cancer Vaccines Price by Manufacturers 2018-2023 (USD/Unit)
Table 20. Global Key Players of Cancer Vaccines, Industry Ranking, 2021 VS 2024
Table 21. Global Cancer Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Cancer Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Vaccines as of 2024)
Table 23. Global Key Manufacturers of Cancer Vaccines, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Cancer Vaccines, Product Offered and Application
Table 25. Global Key Manufacturers of Cancer Vaccines, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Cancer Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 28. Global Cancer Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Cancer Vaccines Sales Quantity Share by Type (2018-2023)
Table 30. Global Cancer Vaccines Sales Quantity Share by Type (2024-2034)
Table 31. Global Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Cancer Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Cancer Vaccines Revenue Share by Type (2018-2023)
Table 34. Global Cancer Vaccines Revenue Share by Type (2024-2034)
Table 35. Cancer Vaccines Price by Type (2018-2023) & (USD/Unit)
Table 36. Global Cancer Vaccines Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Cancer Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 38. Global Cancer Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Cancer Vaccines Sales Quantity Share by Application (2018-2023)
Table 40. Global Cancer Vaccines Sales Quantity Share by Application (2024-2034)
Table 41. Global Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Cancer Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Cancer Vaccines Revenue Share by Application (2018-2023)
Table 44. Global Cancer Vaccines Revenue Share by Application (2024-2034)
Table 45. Cancer Vaccines Price by Application (2018-2023) & (USD/Unit)
Table 46. Global Cancer Vaccines Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Cancer Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 48. North America Cancer Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 49. North America Cancer Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 50. North America Cancer Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 52. North America Cancer Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Cancer Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 54. North America Cancer Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 56. North America Cancer Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Cancer Vaccines Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 58. North America Cancer Vaccines Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Cancer Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Cancer Vaccines Sales Quantity by Country (2018-2023) & (K Units)
Table 61. North America Cancer Vaccines Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Cancer Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 63. Europe Cancer Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 64. Europe Cancer Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 65. Europe Cancer Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 67. Europe Cancer Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Cancer Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 69. Europe Cancer Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 71. Europe Cancer Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Cancer Vaccines Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 73. Europe Cancer Vaccines Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Cancer Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Cancer Vaccines Sales Quantity by Country (2018-2023) & (K Units)
Table 76. Europe Cancer Vaccines Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Cancer Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 78. China Cancer Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 79. China Cancer Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 80. China Cancer Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 82. China Cancer Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Cancer Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 84. China Cancer Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 86. China Cancer Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Cancer Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 88. APAC Cancer Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 89. APAC Cancer Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 90. APAC Cancer Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 92. APAC Cancer Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Cancer Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 94. APAC Cancer Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 96. APAC Cancer Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Cancer Vaccines Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 98. APAC Cancer Vaccines Revenue by Region (2018-2023) & (US$ Million)
Table 99. APAC Cancer Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Cancer Vaccines Sales Quantity by Region (2018-2023) & (K Units)
Table 101. APAC Cancer Vaccines Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Company (2018-2023) & (K Units)
Table 103. Middle East, Africa and Latin America Cancer Vaccines Revenue by Company (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Type (2018-2023) & (K Units)
Table 105. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Cancer Vaccines Revenue by Type (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Cancer Vaccines Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Cancer Vaccines Revenue by Application (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Cancer Vaccines Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Cancer Vaccines Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Cancer Vaccines Revenue by Country (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Cancer Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Country (2018-2023) & (K Units)
Table 116. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Glaxosmithkline Company Information
Table 118. Glaxosmithkline Description and Overview
Table 119. Glaxosmithkline Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 120. Glaxosmithkline Cancer Vaccines Product and Services
Table 121. Glaxosmithkline Cancer Vaccines SWOT Analysis
Table 122. Glaxosmithkline Recent Developments
Table 123. Astellas Pharma Company Information
Table 124. Astellas Pharma Description and Overview
Table 125. Astellas Pharma Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 126. Astellas Pharma Cancer Vaccines Product and Services
Table 127. Astellas Pharma Cancer Vaccines SWOT Analysis
Table 128. Astellas Pharma Recent Developments
Table 129. Merck Company Information
Table 130. Merck Description and Overview
Table 131. Merck Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 132. Merck Cancer Vaccines Product and Services
Table 133. Merck Cancer Vaccines SWOT Analysis
Table 134. Merck Recent Developments
Table 135. CSL Limited Company Information
Table 136. CSL Limited Description and Overview
Table 137. CSL Limited Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 138. CSL Limited Cancer Vaccines Product and Services
Table 139. CSL Limited Cancer Vaccines SWOT Analysis
Table 140. CSL Limited Recent Developments
Table 141. Sanpower Group Company Information
Table 142. Sanpower Group Description and Overview
Table 143. Sanpower Group Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 144. Sanpower Group Cancer Vaccines Product and Services
Table 145. Sanpower Group Cancer Vaccines SWOT Analysis
Table 146. Sanpower Group Recent Developments
Table 147. Sanofi Pasteur Company Information
Table 148. Sanofi Pasteur Description and Overview
Table 149. Sanofi Pasteur Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 150. Sanofi Pasteur Cancer Vaccines Product and Services
Table 151. Sanofi Pasteur Cancer Vaccines SWOT Analysis
Table 152. Sanofi Pasteur Recent Developments
Table 153. Pfizer Company Information
Table 154. Pfizer Description and Overview
Table 155. Pfizer Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 156. Pfizer Cancer Vaccines Product and Services
Table 157. Pfizer Cancer Vaccines SWOT Analysis
Table 158. Pfizer Recent Developments
Table 159. Serum Institute of India Company Information
Table 160. Serum Institute of India Description and Overview
Table 161. Serum Institute of India Cancer Vaccines Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 162. Serum Institute of India Cancer Vaccines Product and Services
Table 163. Serum Institute of India Cancer Vaccines SWOT Analysis
Table 164. Serum Institute of India Recent Developments
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Cancer Vaccines Distributors List
Table 168. Cancer Vaccines Customers List
Table 169. Cancer Vaccines Market Trends
Table 170. Cancer Vaccines Market Drivers
Table 171. Cancer Vaccines Market Challenges
Table 172. Cancer Vaccines Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Vaccines Product Picture
Figure 2. Global Cancer Vaccines Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Cancer Vaccines Market Share by Type in 2024 & 2034
Figure 4. Preventive Cancer Vaccines Product Picture
Figure 5. Therapeutic Cancer Vaccines Product Picture
Figure 6. Global Cancer Vaccines Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Cancer Vaccines Market Share by Application in 2024 & 2034
Figure 8. Cervical Cancer
Figure 9. Prostate Cancer
Figure 10. Others
Figure 11. Cancer Vaccines Report Years Considered
Figure 12. Global Cancer Vaccines Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Cancer Vaccines Revenue 2018-2034 (US$ Million)
Figure 14. Global Cancer Vaccines Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 15. Global Cancer Vaccines Sales Quantity 2018-2034 (K Units)
Figure 16. Global Cancer Vaccines Sales Quantity Market Share by Region (2018-2023)
Figure 17. Global Cancer Vaccines Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Cancer Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Cancer Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Cancer Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Cancer Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Cancer Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Cancer Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Cancer Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Cancer Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Cancer Vaccines Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Cancer Vaccines Sales Quantity in 2024
Figure 29. The Top 10 and Top 5 Players Market Share by Cancer Vaccines Revenue in 2024
Figure 30. Cancer Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 31. Global Cancer Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Cancer Vaccines Revenue Market Share by Type (2018-2034)
Figure 33. Global Cancer Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Cancer Vaccines Revenue Market Share by Application (2018-2034)
Figure 35. North America Cancer Vaccines Revenue Market Share by Company in 2024
Figure 36. North America Cancer Vaccines Sales Quantity Market Share by Company in 2024
Figure 37. North America Cancer Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Cancer Vaccines Revenue Market Share by Type (2018-2034)
Figure 39. North America Cancer Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Cancer Vaccines Revenue Market Share by Application (2018-2034)
Figure 41. North America Cancer Vaccines Revenue Share by Country (2018-2034)
Figure 42. North America Cancer Vaccines Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Cancer Vaccines Sales Quantity Market Share by Company in 2024
Figure 46. Europe Cancer Vaccines Revenue Market Share by Company in 2024
Figure 47. Europe Cancer Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Cancer Vaccines Revenue Market Share by Type (2018-2034)
Figure 49. Europe Cancer Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Cancer Vaccines Revenue Market Share by Application (2018-2034)
Figure 51. Europe Cancer Vaccines Revenue Share by Country (2018-2034)
Figure 52. Europe Cancer Vaccines Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 54. France Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 58. China Cancer Vaccines Sales Quantity Market Share by Company in 2024
Figure 59. China Cancer Vaccines Revenue Market Share by Company in 2024
Figure 60. China Cancer Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Cancer Vaccines Revenue Market Share by Type (2018-2034)
Figure 62. China Cancer Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Cancer Vaccines Revenue Market Share by Application (2018-2034)
Figure 64. APAC Cancer Vaccines Sales Quantity Market Share by Company in 2024
Figure 65. APAC Cancer Vaccines Revenue Market Share by Company in 2024
Figure 66. APAC Cancer Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Cancer Vaccines Revenue Market Share by Type (2018-2034)
Figure 68. APAC Cancer Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Cancer Vaccines Revenue Market Share by Application (2018-2034)
Figure 70. APAC Cancer Vaccines Revenue Share by Region (2018-2034)
Figure 71. APAC Cancer Vaccines Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 76. India Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity Market Share by Company in 2024
Figure 78. Middle East, Africa and Latin America Cancer Vaccines Revenue Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Cancer Vaccines Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Cancer Vaccines Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Cancer Vaccines Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Cancer Vaccines Revenue Share by Country (2018-2034)
Figure 85. Brazil Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Cancer Vaccines Revenue (2018-2034) & (US$ Million)
Figure 90. Cancer Vaccines Value Chain
Figure 91. Cancer Vaccines Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed